Skip to main content

Advertisement

SpringerLink
Log in

The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity

  • Pediatrics
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Recent experimental studies suggest that vascular endothelial growth factor (VEGF) can play an important role in the development of retinopathy of prematurity (ROP). There are interesting observations of VEGF concentration in the serum, depending on its gene polymorphism which can have an impact on abnormal vessel development in the retina.

Aim

Analysis of: (1) association of VEGF gene polymorphisms and the incidence of ROP, (2) correlation between serum concentration of VEGF and soluble VEGF receptor 1 (sVEGFR-1) during the 1st month of life and the risk of ROP, and (3) correlation between VEGF gene polymorphisms and VEGF serum concentrations.

Methods

A sample of 181 newborns with mean birthweight 1054 g (range: 500–1500 g) was prospectively evaluated. Molecular analysis of VEGF −460T>C and 405G>C polymorphisms were performed in the whole studied population, and concentrations of VEGF and sVEGFR-1 were measured by Elisa assay in the 2nd, 3rd and 4th weeks of life in the group of 128 children. The infants were divided into 3 groups: A) no ROP (n = 101), B) ROP not requiring treatment (n = 20), and C) ROP requiring laser or cryotherapy (n = 60).

Results

The frequency of VEGF 405G>C polymorphism was similar in all studied groups. The carriage of polymorphic allele −460 T was significantly overrepresented in ROP newborns who required treatment as compared to the no ROP group (54.2% vs 42.6%; OR: 1.63; 95% CI: 1.03–2.55). VEGF serum concentrations in the patients ascribed to different groups depending on the 405G>C or −460 T>C polymorphisms were similar. VEGF and sVEGFR−1 concentration on the 10th day of life did not differ significantly between the studied groups. Consecutive measurements showed a gradual increase in VEGF serum concentration in children without ROP, whereas in children with ROP requiring treatment the levels remained low.

Conclusions

Based on our observations and previously published data, the association of the VEGF gene promoter polymorphisms and the risk of advanced ROP is weak. VEGF serum concentration assessment as early as on the 20th day of life appears to be a promising approach to recognize newborns at risk of the development of advanced ROP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Haines JL, Fielder A, Baker H, Wilkinson AR (2005) UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 90:240–244

    Article  Google Scholar 

  2. Kaiser RS, Trese MT, Williams GA, Cox MS (2001) Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 108:1647–1653

    Article  PubMed  CAS  Google Scholar 

  3. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115:e518–e525

    Article  PubMed  Google Scholar 

  4. Tompkins C (2001) A sudden rise in the prevalence of retinopathy of prematurity blindness? Pediatrics 108:526–526

    Article  PubMed  CAS  Google Scholar 

  5. Palmer EA (2003) Implications of the Natural Course of Retinopathy of Prematurity. Pediatrics 111:885–886

    Article  PubMed  Google Scholar 

  6. Holmstrom GE, Broberger U, Thomassen P (1998) Neonatal risk factors for retinopathy of prematurity-a population- based study. Acta Ophthalmol Scand 76:204–207

    Article  PubMed  CAS  Google Scholar 

  7. Karna P, Muttineni J, Angell L, Karmaus W (2005) Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 5:18

    Article  PubMed  Google Scholar 

  8. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM (2002) Retinopathy of prematurity: recent advances of our understanding. Arch Dis Child Fetal Neonatal Ed 87:F78–F82

    Article  PubMed  CAS  Google Scholar 

  9. Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, Hardy RJ (1993) Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 100:230–237

    PubMed  CAS  Google Scholar 

  10. Hutchinson AK, O’Neil JW, Morgan EN, Cervenak MA, Saunders RA (2003) Retinopathy of prematurity in infants with birth weights greater than 1250 grams. J AAPOS 7:190–194

    Article  PubMed  Google Scholar 

  11. Bizzarro MJ, Hussain N, Jonsson B, Feng R, Ment LR, Gruen JR, Zhang H, Bhandari V (2006) Genetic Susceptibility to Retinopathy of Prematurity. Pediatrics 118:1858–1863

    Article  PubMed  Google Scholar 

  12. Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, Phelps DL (1997) Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 115:604–608

    PubMed  CAS  Google Scholar 

  13. Arnold RW, Kesler K, Avila E (1994) Susceptibility to retinopathy of prematurity in Alaskan Natives. J Pediatr Ophthalmol Strabismus 31:192–194

    PubMed  CAS  Google Scholar 

  14. Smith LE (2005) IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate 88:237–244

    Article  PubMed  CAS  Google Scholar 

  15. Sennlaub F, Chemtob S (2004) VEGFR-1: a safe target for prophylaxis of retinopathy of prematurity? Pediatr Res 55:1–2

    Article  PubMed  Google Scholar 

  16. Shastry BS, Qu X (2007) Lack of association of the VEGF gene promoter (−634 G−>C and −460 C−>T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:741–743

    Article  PubMed  CAS  Google Scholar 

  17. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB (1996) Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet 97:794–797

    Article  PubMed  CAS  Google Scholar 

  18. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448

    Article  PubMed  CAS  Google Scholar 

  19. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity - Results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol 121:1684–1696

    Article  PubMed  CAS  Google Scholar 

  20. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639

    Article  PubMed  CAS  Google Scholar 

  21. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, Osaki M, Watanabe M, Nakashima Y, Inukai K, Inoue I, Kawasaki I, Mori K, Yoneya S, Katayama S (2005) Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333:679–685

    Article  PubMed  CAS  Google Scholar 

  22. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, Sundaresan P (2006) Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 12:336–341

    PubMed  CAS  Google Scholar 

  23. Banyasz I, Bokodi G, Vannay A, Szebeni B, Treszl A, Vasarhelyi B, Tulassay T, Szabo A (2006) Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 31:685–690

    Article  PubMed  CAS  Google Scholar 

  24. Cooke RW, Drury JA, Mountford R, Clark D (2004) Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci 45:1712–1715

    Article  PubMed  Google Scholar 

  25. Vannay A, Dunai G, Banyasz I, Szabo M, Vamos R, Treszl A, Hajdu J, Tulassay T, Vasarhelyi B (2005) Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 57:396–398

    Article  PubMed  CAS  Google Scholar 

  26. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816

    PubMed  CAS  Google Scholar 

  27. Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY (2005) Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod 20:2904–2908

    Article  PubMed  CAS  Google Scholar 

  28. Pierce EA, Folez ED, Smith LE (1996) Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity. Arch Ophthalmol 114:1219–1228

    PubMed  CAS  Google Scholar 

  29. Leske DA, Wu J, Mookadam M, Chen Y, Fautsch MP, Holmes JM, Lanier WL (2006) The relationship of retinal VEGF and retinal IGF-1 mRNA with neovascularization in an acidosis-induced model of retinopathy of prematurity. Curr Eye Res 31:163–169

    Article  PubMed  CAS  Google Scholar 

  30. Leske DA, Wu J, Fautsch MP, Karger RA, Berdahl JP, Lanier WL, Holmes JM (2004) The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol Vis 10:43–50

    PubMed  CAS  Google Scholar 

  31. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS (2004) Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 79:623–630

    Article  PubMed  CAS  Google Scholar 

  32. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY (2000) Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 41:2115–2119

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Jagiellonian University, 30-663, Cracow, Poland

    Przemko Kwinta, Mirosław Bik-Multanowski, Zofia Mitkowska, Tomasz Tomasik & Jacek J. Pietrzyk

Authors
  1. Przemko Kwinta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mirosław Bik-Multanowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zofia Mitkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomasz Tomasik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacek J. Pietrzyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Przemko Kwinta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwinta, P., Bik-Multanowski, M., Mitkowska, Z. et al. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246, 1467–1475 (2008). https://doi.org/10.1007/s00417-008-0865-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0865-9

Keywords

Search

Navigation